Acumen Pharmaceuticals, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-03-11$3.37 RISE2026-05-19$2.17 PEAK2026-05-29$2.60 79d | -35.6% 69d | Missed | Missed | — | — | +19.8% 10d | Missed |
DROP2026-03-11$3.37 RISE2026-03-30$2.19 PEAK2026-04-20$2.84 40d | -35.0% 19d | Missed | Missed | — | — | +29.7% 21d | Missed |
DROP2025-10-14$2.33 RISE2026-01-12$1.72 PEAK2026-03-11$3.37 148d | -26.2% 90d | Missed | Missed | — | — | +95.9% 58d | Missed |
DROP2025-10-14$2.33 RISE2025-11-19$1.55 PEAK2026-01-28$2.81 106d | -33.5% 36d | Missed | Missed | — | — | +81.3% 70d | Missed |
DROP2025-07-23$1.68 RISE2025-09-23$1.23 PEAK2025-10-14$2.33 83d | -26.8% 62d | Missed | Missed | — | — | +89.4% 21d | Missed |
DROP2025-07-23$1.68 RISE2025-09-16$1.23 PEAK2025-10-14$2.33 83d | -26.8% 55d | Missed | Missed | — | — | +89.4% 28d | Missed |
DROP2025-07-23$1.68 RISE2025-08-12$1.26 PEAK2025-10-14$2.33 83d | -25.0% 20d | Missed | Missed | — | — | +84.9% 63d | Missed |
DROP2024-12-09$2.25 RISE2025-04-17$0.90 PEAK2025-07-14$1.49 217d | -60.0% 129d | Missed | Missed | — | — | +65.4% 88d | Missed |
DROP2024-07-23$3.54 RISE2024-10-10$2.25 PEAK2024-11-08$3.27 108d | -36.4% 79d | Missed | Missed | — | — | +45.3% 29d | Missed |
DROP2024-05-20$3.84 RISE2024-09-06$2.22 PEAK2024-11-08$3.27 172d | -42.2% 109d | Missed | Missed | — | — | +47.3% 63d | Missed |
DROP2024-03-01$4.64 RISE2024-06-25$2.14 PEAK2024-07-23$3.54 144d | -53.9% 116d | Missed | Missed | — | — | +65.4% 28d | Missed |
DROP2024-03-01$4.64 RISE2024-04-22$3.13 PEAK2024-05-20$3.84 80d | -32.5% 52d | Missed | Missed | — | — | +22.7% 28d | Missed |
DROP2023-10-05$4.48 RISE2024-02-02$2.97 PEAK2024-03-01$4.64 148d | -33.7% 120d | Missed | Missed | — | — | +56.2% 28d | Missed |
DROP2023-07-17$9.72 RISE2023-11-09$1.86 PEAK2024-01-09$4.35 176d | -80.9% 115d | Missed | Missed | — | — | +133.9% 61d | Missed |
DROP2023-05-10$6.59 RISE2023-06-27$4.77 PEAK2023-07-17$9.72 68d | -27.6% 48d | Missed | Missed | — | — | +103.8% 20d | Missed |
1–15 / 24 1 / 2 | |||||||
ABOS outlook: sabirnetug and the ALTITUDE-AD Phase 2 readout are key to 2026 upside.
Acumen Pharmaceuticals, Inc. (ABOS) Bank of America Global Healthcare Conference 2026 May 14, 2026 11:55 AM EDTCompany ParticipantsDaniel O'Connell - CEO...
Presenter SpeechJason Zemansky Last day of Bank of America's Annual Healthcare Conference and a very, very warm Las Vegas. My name is Jason Zemansky. I'm one of the mid-cap analyst here at BofA.
Acumen Pharmaceuticals Inc (ABOS) showcases promising developments in Alzheimer's treatment and cost management, despite reporting a net loss for the quarter.
Acumen Pharmaceuticals (NASDAQ:ABOS) said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on track, with top-line results expected late in 2026, as the company continues to advance its broader Alzheimer’s disease pipeline. On the company’s first-quarter 2026 earnings call, Chief Executive Offic
Acumen Pharmaceuticals Q1 2026 loss beat estimates as Phase 2 Alzheimer's trial for sabirnetug nears late 2026 readout. Cash runway extends into early 2027.
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call May 12, 2026 8:00 AM EDTCompany ParticipantsAlex Braun - VP & Head of Investor RelationsDaniel...
Presentation Operator MessageOperator Good day, and thank you for standing by. Welcome to the Acumen Pharma First Quarter 2026 Conference Call and Webcast. [Operator Instructions] Please be advised...
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug for the treatment of early Alzheimer’s disease, in late 2026Lead clinical candidate IND filing in...
Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 31.25 percent increase over losses of $(0.48) per share
NEWTON, Mass., May 07, 2026 -- Acumen Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the...
NEWTON, Mass., May 05, 2026 -- Acumen Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the...
The heavy selling pressure might have exhausted for Acumen Pharmaceuticals (ABOS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compared to their sector so far this year.
Moby summary of Acumen Pharmaceuticals, Inc.'s Q4 2025 earnings call
Acumen Pharmaceuticals Inc (ABOS) reports significant clinical progress and strategic partnerships, despite increased R&D expenses and a net loss for 2025.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ABOS | +9.24% | -21.21% | +23.22% | +154.90% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +6.27% | -15.50% | +26.67% | +142.21% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 1.16M | $2.73M | 0.00% | Trimmed-42.9% | 2026-03-31 |
| TwoSigma | quant | 530.8K | $1.25M | 0.00% | Added+270.6% | 2026-03-31 |
| RenTech | quant | 473.9K | $1.12M | 0.00% | Added+12.0% | 2026-03-31 |
| StateStreet | passive | 151.7K | $358.08K | 0.00% | Added+51.5% | 2026-03-31 |
| Citadel | multi-strat | 67.4K | $159.00K | 0.00% | Added+85.3% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-18 | RA CAPITAL MANAGEMENT, L.P. | Director · 10% Owner | A Grant / award | 6,060,606 | $3.30 | +$20.00M |
| 2026-03-10 | Meisner Derek M | Chief Legal Officer & Corp Sec | M Option exercise(deriv) | 2,090 | — | +$0 |
| 2026-03-10 | Meisner Derek M | Chief Legal Officer & Corp Sec | S Open-market sale | 2,090 | $3.26 | −$6.8K |
| 2026-03-10 | Meisner Derek M | Chief Legal Officer & Corp Sec | M Option exercise | 2,090 | $1.85 | +$3.9K |
| 2026-03-03 | Meisner Derek M | Chief Legal Officer & Corp Sec | M Option exercise(deriv) | 9,406 | — | +$0 |
| 2026-03-03 | Meisner Derek M | Chief Legal Officer & Corp Sec | S Open-market sale | 9,406 | $3.01 | −$28.3K |
| 2026-03-03 | Meisner Derek M | Chief Legal Officer & Corp Sec | M Option exercise | 9,406 | $1.85 | +$17.4K |
| 2026-01-28 | Meisner Derek M | Chief Legal Officer & Corp Sec | M Option exercise(deriv) | 2,671 | — | +$0 |
| 2026-01-28 | Meisner Derek M | Chief Legal Officer & Corp Sec | M Option exercise(deriv) | 15,085 | — | +$0 |
| 2026-01-28 | Meisner Derek M | Chief Legal Officer & Corp Sec | S Open-market sale | 2,671 | $3.00 | −$8.0K |
| 2026-01-28 | Meisner Derek M | Chief Legal Officer & Corp Sec | M Option exercise | 2,671 | $1.85 | +$4.9K |
| 2026-01-28 | Meisner Derek M | Chief Legal Officer & Corp Sec | S Open-market sale | 15,085 | $3.00 | −$45.3K |
| 2026-01-28 | Meisner Derek M | Chief Legal Officer & Corp Sec | M Option exercise | 15,085 | $1.85 | +$27.9K |
| 2026-01-23 | Barton Russell | Chief Operating Officer | S Open-market sale | 462 | $1.84 | −$850 |
| 2026-01-23 | Barton Russell | Chief Operating Officer | S Open-market sale | 2,315 | $1.81 | −$4.2K |
| 2026-01-23 | OConnell Daniel Joseph | Chief Executive Officer | S Open-market sale | 2,689 | $1.88 | −$5.1K |
| 2026-01-23 | OConnell Daniel Joseph | Chief Executive Officer | S Open-market sale | 9,346 | $1.81 | −$16.9K |
| 2026-01-23 | Zuga Matt | CFO & Chief Business Officer | S Open-market sale | 1,687 | $1.86 | −$3.1K |
| 2026-01-23 | Zuga Matt | CFO & Chief Business Officer | S Open-market sale | 2,473 | $1.81 | −$4.5K |
| 2026-01-23 | Siemers Eric | Chief Medical Officer | S Open-market sale | 895 | $1.82 | −$1.6K |
| 2026-01-23 | Siemers Eric | Chief Medical Officer | S Open-market sale | 2,331 | $1.80 | −$4.2K |
| 2026-01-23 | Meisner Derek M | Chief Legal Officer & Corp Sec | S Open-market sale | 5,633 | $1.90 | −$10.7K |
| 2026-01-23 | Meisner Derek M | Chief Legal Officer & Corp Sec | S Open-market sale | 1,054 | $1.84 | −$1.9K |
| 2026-01-23 | Meisner Derek M | Chief Legal Officer & Corp Sec | S Open-market sale | 2,247 | $1.81 | −$4.1K |
| 2026-01-21 | Doherty James J. | President and CDO | A Grant / award(deriv) | 250,300 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-11upcoming | -0.42 | — | — |
| 2026-05-12 | -0.36 | -0.33 | +9.59% |
| 2026-03-26 | -0.56 | -0.41 | +26.29% |
| 2025-11-12 | -0.68 | -0.44 | +35.23% |
| 2025-08-12 | -0.52 | -0.68 | -31.13% |
| 2025-05-13 | -0.55 | -0.48 | +12.09% |
| 2025-03-27 | -0.37 | -0.62 | -69.48% |
| 2024-11-12 | -0.30 | -0.50 | -68.46% |
| 2024-08-13 | -0.25 | -0.34 | -35.33% |
| 2024-05-14 | -0.23 | -0.25 | -6.58% |
| 2024-03-26 | -0.25 | -0.29 | -15.63% |
| 2023-11-13 | -0.26 | -0.24 | +8.50% |
| 2023-08-08 | -0.34 | -0.28 | +17.65% |
| 2023-05-09 | -0.33 | -0.28 | +15.15% |
| 2023-03-27 | -0.23 | -0.32 | -38.08% |
| 2022-11-14 | -0.20 | -0.26 | -28.34% |